Etravirine is metabolized by three cytochrome P450 enzymes that are in turn induced by rifampin. Consequently, co-administration of etravirine and rifampin is not recommended. To date, however, no clinical studies exploring the drug-drug interaction of this combination have been conducted. Here we report two cases of off-label etravirine use concurrently with antitubercular treatment, dictated by the unavailability of other treatments. Plasma drug concentrations were monitored by regular measurements. Our results appear to confirm the increased metabolism of etravirine through the induction of cytochrome P450 enzymes, but the adequacy of drug levels in all of the measurements and subsequent virological suppression suggest that this drug interaction may not be clinically relevant.

Gagliardini, R., Fabbiani, M., Fortuna, S., Visconti, E., Navarra, P., Cauda, R., Colafigli, M., De Luca, A., Trecarichi, E. M., Di Giambenedetto, S., Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis, <<INFECTION>>, N/A; 2014 (Febbraio): N/A-N/A. [doi:10.1007/s15010-014-0599-z] [http://hdl.handle.net/10807/54201]

Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis

Gagliardini, Roberta;Fabbiani, Massimiliano;Fortuna, Serena;Visconti, Elena;Navarra, Pierluigi;Cauda, Roberto;Colafigli, Manuela;De Luca, Andrea;Trecarichi, Enrico Maria;Di Giambenedetto, Simona
2014

Abstract

Etravirine is metabolized by three cytochrome P450 enzymes that are in turn induced by rifampin. Consequently, co-administration of etravirine and rifampin is not recommended. To date, however, no clinical studies exploring the drug-drug interaction of this combination have been conducted. Here we report two cases of off-label etravirine use concurrently with antitubercular treatment, dictated by the unavailability of other treatments. Plasma drug concentrations were monitored by regular measurements. Our results appear to confirm the increased metabolism of etravirine through the induction of cytochrome P450 enzymes, but the adequacy of drug levels in all of the measurements and subsequent virological suppression suggest that this drug interaction may not be clinically relevant.
2014
Inglese
Gagliardini, R., Fabbiani, M., Fortuna, S., Visconti, E., Navarra, P., Cauda, R., Colafigli, M., De Luca, A., Trecarichi, E. M., Di Giambenedetto, S., Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis, <<INFECTION>>, N/A; 2014 (Febbraio): N/A-N/A. [doi:10.1007/s15010-014-0599-z] [http://hdl.handle.net/10807/54201]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/54201
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact